Can a targeted drug boost standard chemo for aggressive lymphoma?
NCT ID NCT07744737
First seen Aug 04, 2026 · Last updated Aug 07, 2026 · Updated 3 times
Summary
This trial is testing whether adding pirtobrutinib, a targeted drug, to the standard R-CHOP chemotherapy regimen can improve outcomes for people with a specific subtype of diffuse large B-cell lymphoma (non-GCB DLBCL). The study will enroll about 34 adults with newly diagnosed disease who have not received prior treatment. Participants will receive pirtobrutinib alongside R-CHOP for six cycles, and researchers will measure how many achieve a complete response, along with safety and survival outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pirtobrutinib combined with R-CHOP chemotherapy
- What this could lead to
- If successful, this combination could offer a more effective first-line treatment for a hard-to-treat subtype of DLBCL, potentially improving remission rates and long-term outcomes.
- What could go wrong
- This is a small phase 2 study, so results may not be definitive. Adding pirtobrutinib to standard chemo could increase side effects, and the benefit over standard R-CHOP alone is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jiangsu Province Hospital The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Four-Pronged attack beat brain lymphoma?
- Can a new drug combo outsmart resistant lymphomas?
- Can a targeted drug combo outsmart an aggressive lymphoma?
- Can a reshaped chemo combo tame lymphoma with fewer side effects?
- New drug cocktail aims to outsmart aggressive blood cancer
- Targeted combo aims at tough lymphoma subtype